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Background: Cardiovascular Magnetic Resonance (CMR) imaging is accurate and reproducible for the assessment
of right ventricular (RV) morphology and function. However, the diagnostic accuracy of CMR derived RV
measurements for the detection of pulmonary hypertension (PH) in the assessment of patients with suspected PH
in the clinic setting is not well described.
Methods: We retrospectively studied 233 consecutive treatment naïve patients with suspected PH including 39
patients with no PH who underwent CMR and right heart catheterisation (RHC) within 48hours. The diagnostic
accuracy of multiple CMR measurements for the detection of mPAP≥ 25 mmHg was assessed using Fisher’s exact
test and receiver operating characteristic (ROC) analysis.
Results: Ventricular mass index (VMI) was the CMR measurement with the strongest correlation with mPAP
(r = 0.78) and the highest diagnostic accuracy for the detection of PH (area under the ROC curve of 0.91) compared
to an ROC of 0.88 for echocardiography calculated mPAP. Late gadolinium enhancement, VMI≥ 0.4, retrograde
flow≥ 0.3 L/min/m2 and PA relative area change≤ 15% predicted the presence of PH with a high degree of
diagnostic certainty with a positive predictive value of 98%, 97%, 95% and 94% respectively. No single CMR
parameter could confidently exclude the presence of PH.
Conclusion: CMR is a useful alternative to echocardiography in the evaluation of suspected PH. This study supports
a role for the routine measurement of ventricular mass index, late gadolinium enhancement and the use of phase
contrast imaging in addition to right heart functional indices in patients undergoing diagnostic CMR evaluation for
suspected pulmonary hypertension.
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Pulmonary Hypertension (PH) is defined as a mean pul-
monary artery pressure (mPAP) greater than or equal to
25 mmHg measured at cardiac catheterisation [1]. It
ranges from a rare, progressive condition characterised
by a vasculopathy, pulmonary arterial hypertension
(PAH), to mild elevations of pulmonary artery pressure
commonly seen in association with respiratory and car-
diac disease. In patients with PAH an increase in mPAP
and pulmonary vascular resistance (PVR) results in right
ventricular failure and death with a median survival in
untreated patients of less than 3 years [2,3].
Right heart catheterisation (RHC) is the gold standard
test used to assess for the presence or absence of PH by
directly measuring mPAP and allows measurement of
cardiac output (CO) and index (CI), right atrial pressure,
mixed venous oxygen saturation and PVR, which are
used as markers of disease severity. However, although
safe in expert hands it is an invasive test and its role is
limited to confirming a diagnosis of PH and in selected
cases assessing the response to treatment. Echocardiog-
raphy is currently the most commonly used non-
invasive test in patients with suspected PH, however, this
technique has a number of limitations and does not per-
form well for certain aetiologies of PH [4,5], significantly
over and underestimating invasively measured mPAP
[6]. Consequently, there is increasing interest in develop-
ing other non-invasive imaging tools.
Several studies have shown significant relationships
between cardiovascular magnetic resonance (CMR)
derived measurements with mPAP and PVR in patients
with PH; including ventricular mass index (VMI) [7-11],
inter-ventricular septal configuration [12-14], pulmonary
arterial blood flow quantification and pulsatility [10,15-
18]. However, these studies have primarily been limited
to patients with PAH and the diagnostic utility of CMR
measurements in a large population of unselected
patients with PH has not been evaluated.
The aim of this study was to compare the diagnostic
accuracy of a variety of CMR parameters to identify PH
confirmed at cardiac catheterisation in unselected
patients with suspected PH attending a referral centre.
Methods
Patients
Consecutive treatment naive patients undergoing RHC
and CMR for suspected PH were identified between
January 2008 and March 2010 at a high volume nation-
ally designated PH referral centre. All incident patients
with suspected PH routinely undergo CMR as part of
their diagnostic work-up. Inclusion criteria required the
patients’ RHC and CMR to be within 48 h, and patients
were excluded if the imaging was of non-diagnostic
quality. Other exclusion criteria were as per standardcriteria for patients undergoing CMR. Approval for
retrospective analysis of imaging techniques was granted
by the local research ethics committee.
CMR acquisition
CMR was performed on a 1.5 T whole body scanner GE
HDx (GE Healthcare, Milwaukee, USA), using an 8 chan-
nel cardiac coil. 4 chamber and short axis cine images
were acquired using a cardiac gated multi-slice balanced
steady state free precession sequence (20 frames per car-
diac cycle, slice thickness 8 mm, FOV 48, matrix
256 × 256, BW 125 KHz/pixel, TR/TE 3.7/1.6 ms). A
stack of images in the short axis plane with slice thick-
ness of 8 mm (2 mm inter-slice gap) were acquired fully
covering both ventricles from base to apex. For short axis
imaging end-systole was considered to be the smallest
cavity area. End-systole was defined as maximal RV
shortening on the 4 chamber slice images. End-diastole
was defined as the first cine phase of the R-wave trig-
gered acquisition for both short axis and four chamber
imaging. Ten minutes following gadolinium contrast in-
jection (0.1 mmol/kg of gadolinium-DTPA; Gadovist,
Bayer, Germany), late-enhancement imaging was per-
formed using a 3D-gradient spoiled echo sequence (repe-
tition time 7.7 ms, echo time 3.6 ms, TI 180 ms, slice
thickness 8 mm, FOV 45 × 40.5,matrix 256 × 224). Select-
ive 180° inversion-recovery images were acquired in the
short axis obtaining limited 3–5 slices through the ven-
tricles. We have corrected our MR parameters where ap-
propriate for body surface area, as previously reported in
the literature [19]. Phase contrast imaging parameters
were as follows: repetition time 5.6 ms, echo time 2.7 ms,
slice thickness 10 mm, FOV 48 × 28.8, band-width
62.5 kHz, matrix = 256 × 128, 20 reconstructed cardiac
phases and velocity encoding 150 cm/s in the slice direc-
tion. Phase contrast imaging was performed orthogonal
to the pulmonary arterial (PA) trunk Studies were per-
formed with patients in the supine position with a sur-
face coil and with retrospective ECG gating.
Image analysis
Image analysis was performed on a GE Advantage
Workstation 4.1 by a pulmonary vascular radiologist
(AS) (with 2 years specialist experience in CMR) who
was blinded to the patient clinical information, and car-
diac catheter parameters. Patient’s scans were defined as
non-diagnostic when image quality significantly affected
cardiac measurements or volumetric analysis could not
be accurately performed.
RV ejection fraction (RVEF), end-diastolic volume (RVEDVI),
stroke volume (RVSVI)
Endocardial surfaces were manually traced from the stack
of short-axis cine images, using our MR workstation
Figure 1 Short axis slice through the ventricles showing
epicardial and endocardial border segmentation of the RV
(white) and the LV (red). The inter-venticular septum is included in
the LV mass, Ventricular mass index (VMI) is defined as RV mass
divided by LV mass. The endocardial borders of the RV and LV were
traced for calculation of end-diastolic volume (EDV) and end-systolic
volume (ESV). EDV and ESV were calculated by summation of the
product (area × slice distance) for all slices. SV is given by SV = EDV-
ESV calculated for both RV and LV.
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tain RV end-diastolic and end-systolic volumes. From
end-diastolic volume and end-systolic volumes, the RVEF
and RVSV were calculated. RVSVI was defined as RVSV/
body surface area (BSA) measured in ml/m2, see Figure 1.
RV mass index and ventricular mass index (VMI)
The RV epicardial and endocardial borders on each end-
diastolic short axis slice image were outlined. The IVS was
considered as part of the LV. The myocardial volume for
each slice was calculated by multiplying the area of the RV
wall by the slice thickness. The product of the sum total of
the myocardial slice volumes for each ventricle and the
density of myocardium (1.05 g/cm3) gave an estimate of
RV mass[9]. RV mass index was defined as RV mass/body
surface area (BSA) measured in g/m2. The LV epicardial
and endocardial borders on each end-diastolic short axis
slice were outlined, LV end diastolic mass was thus derived.
VMI was defined as RV mass divided by LV mass, Figure 1.
RV relative area change (RVRAC)
The endocardial contours at end-diastole and end-systole
were manually segmented. RVRAC expressed as a percent-
age was calculated from the 4 chamber plane images using
the following formula: RAC=100[(Diastolic area-Systolic
area)/Diastolic area].
Longitudinal function
Longitudinal RV motion was assessed using Tricuspid An-
nular Plane Systolic Excursion (TAPSE), a measurementpreviously evaluated using echocardiography and MRI [20-
22]. TAPSE was calculated manually from the change of
the tricuspid annulus-apex distance between end-diastole
and end-systole 4-chamber images. Fractional measure of
longitudinal motion utilised the tricuspid annulus apex dis-
tance change (fractional-TAAD) and was calculated as
TAPSE divided by the tricuspid annulus-apex dimension at
end-diastole expressed as a percentage. This method was
previously described by Kind et al. [22].
Transverse function
Transverse RV function was determined from the
change of the septum-free-wall perpendicular distance
(SFD) at the mid-point between the apex and the base.
This was measured manually as the change between the
SFD at end-diastole and SFD at end-systole on the 4-
chamber images. Fractional-SFD was calculated as for
fractional longitudinal function [22].
Left ventricular eccentricity
Left ventricular eccentricity measurements have been
traditionally expressed as the ratio of the length of two
LV perpendicular minor-axis diameters [23]. Systolic ec-
centricity index measurements were obtained from the
mid-chamber SA end-systolic image, the ratio was calcu-
lated by the formula sEI =D2/D1, where D2 is the diam-
eter parallel and D1 is perpendicular to the IVS.
Abnormal values derived from echocardiography are
considered to be> 1.2 [23]. dEI was calculated from the
mid-chamber SA end-diastolic image using methods as
described.
Phase contrast indices – PA (n = 106)
Phase contrast CMR was performed at our institution
beginning May 2009. Phase contrast Q flow CMR was
analysed using Reportcard software. The following indi-
ces were generated: average velocity (cm/s), retrograde
flow (L/min) and percentage retrograde flow (%) Max-
imal and minimal pulmonary artery areas were recorded,
and relative area change (RAC) was defined by the fol-
lowing: (maximal area-minimum area)/minimum area.
Late gadolinium enhancement CMR
Late enhancement images were qualitatively assessed for
hyper-intensity at the inter-ventricular septal hinge
points or along the septum as previously described. The
presence or absence of delayed enhancement was
recorded.
Echocardiography
Echocardiography was performed using Powervision
6000 and 8000 machines (Toshiba, Japan) by trained car-
diac physiologists as part of routine clinical care at a
high volume PH referral centre using a standard
Table 1 Patient Subgroup Classification
Clinical classification of PH patients as per Dana Point [24]
Gp1 PAH (n = 83)
Idiopathic 28
PAH Connective tissue diseases 39
PAH Portal hypertension 5
PAH Congenital heart disease 11
Gp2 PH due to left heart disease (n = 21)
LV Diastolic dysfunction 21
Gp3 PH due to lung diseases and/or hypoxia (n = 29)
Chronic obstructive pulmonary disease 19
Interstitial lung disease 5
Mixed obstructive and restrictive 7
Gp4 CTEPH 59
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to obtain the optimal Doppler estimation of tricuspid
regurgitant jet velocity (TRJV) and tricuspid gradient
(TG) calculated using the modified Bernoulli equation,
TG= 4 x TRJV2 . Saline agitation was not used. Right
atrial pressure was estimated from the diameter and re-
spiratory variation of the inferior vena cava. Estimates of
right atrial pressure and TRJV were used to estimate PA
systolic pressure (PA systolic pressure = tricuspid gradi-
ent + estimated right atrial pressure). For the purpose of
comparison with right heart catheter measures of MPAP
and CMRI estimates, MPAP was defined as 0.61 x PA
systolic pressure + 2 mmHg [6].
RHC and clinical evaluation
RHC was performed using a balloon-tipped 7.5 Fr ther-
modilution catheter (Becton-Dickinson, USA). Patients
referred for the investigation of suspected PH also
underwent clinical evaluation including; blood testing,
echocardiography, computed tomography scanning, lung
function testing, exercise testing and perfusion lung
imaging. Diagnostic classification of the form of PH
was by standard criteria following multidisciplinary
assessment [24].
Statistics
Comparisons of CMR measurements between ‘No PH’
and PH patients were analysed using the independent t-
test for continuous data, the chi-square for categorical
data and anova testing with bonferroni corrections for
multiple variables. Pearson’s correlation coefficient was
used to assess the correlations between CMR parameters
and RHC values. Receiver operating characteristic
(ROC) analysis was used to test the diagnostic strength
of CMR parameters for the detection of the presence or
absence of PH. ROC curve analysis results are presented
as area under the curve (AUC). The sensitivity, specifi-
city, negative and positive predictive values of CMR indi-
ces for determining the presence or absence of PH was
assessed using Fisher’s exact test. A p-value< 0.05 was
considered statistically significant. To perform and dis-
play the statistics, SPSS 18 (SPSS, Chicago, Ill) and
GraphPad Prism 5.03 (GraphPad Software, San Diego,
Calif ) software were used.
Results
548 incident, treatment naïve patients who had under-
gone investigation for suspected PH with a right heart
catheter based approach were identified from our PH
database between January 2008 and March 2010. 244
patients underwent CMR and RHC within 48 h of each
other. 11 patients (5%) were excluded as their CMR
scans were degraded by artefact and hence cardiac mea-
surements and volumetric analysis could not be reliablyperformed in these patients. Of the remaining 233
patients, 194 had PH as defined by mPAP ≥ 25 mmHg,
the remaining 39 were labelled as ‘no PH’. Patients with
PH were divided into subgroups according to the Dana
Point classifications, see Table 1 [24]. 106 patients
underwent CMR including phase contrast imaging and
RHC between May 2009 and March 2010, and 159
patients underwent late gadolinium enhancement im-
aging. Echocardiography was performed in 195 of 233
patients at our institution. Scans in the remaining
patients were performed at other institutions prior to re-
ferral and were excluded from analysis. Echocardiog-
raphy was in most cases performed prior to RHC with a
mean interval 35 ± 50 days. A flow chart of the study
profile is shown in Figure 2.Group and subgroup comparisons
Demographic information and RHC data are shown in
Table 2. Patient age, male to female ratio and body sur-
face area (BSA) were not significantly different between
the PH and ‘No PH’ groups. Significantly higher values
of RVEDVI, RV mass, sEI and dEI were demonstrated in
the PH group, and significantly lower values of TAPSE,
f-TAAD, SFD, f-SFD, RVEF, RVSVI and RVRAC were
found in the PH group as compared to the ‘No PH’
group. Derived from phase contrast imaging, PA retro-
grade flow, systolic area and diastolic area were signifi-
cantly higher in patients with PH, whereas PA average
velocity and relative area change were significantly lower
in patients with PH than those without PH (Table 2).
Comparisons between subgroups of PH are shown in
Table 3 and demonstrate that patients with severe pre-
capillary PH such as IPAH and CTEPH have signifi-
cantly worse RV function and mass than patients with
PH owing to left heart disease.
Figure 2 Flow chart of study profile.
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Ventricular mass index demonstrated the strongest cor-
relation of all quantitative MR measurements with mPAP
(r = 0.78; p< 0.0001) and PVR (r = 0.74; p< 0.0001). Echo
predicted mPAP correlated well with mPAP (r = 0.74;
p< 0.0001), and with PVR (r = 0.74; p< 0.0001), Figure 3.
sEI demonstrated a strong correlation with mPAP
(r = 0.71; p< 0.0001) and PVR (r = 0.66; p< 0.0001), dEI
demonstrated a significant though weaker correlations
with mPAP, (r = 0.45; p< 0.0001) and PVR (r = 0.43;
p< 0.0001). PA average velocity and PA relative area
change demonstrated moderate negative linear correla-
tions with mPAP r =−0.55, p< 0.0001 and r =−0.54,
p <0.0001 respectively. Table 4 presents the correlations
between all right ventricular morphological and func-
tional MR indices with invasive haemodynamic metrics
of mPAP and PVR.
Diagnostic accuracy
VMI and RV mass index were the CMR measurements
with the highest diagnostic accuracy for the identifica-
tion of PH from ROC curve analysis (AUC 0.91 for
both), Figure 4. Identification of late gadolinium en-
hancement at the inter-ventricular hinge points was sen-
sitive (83%) and specific (94%) for the identification of
PH (AUC 0.89). Measures of right ventricular functionwere of only modest diagnostic accuracy for determining
the presence of PH.
PA relative area change (AUC 0.87), PA retrograde
flow (AUC 0.84), diastolic PA area (AUC 0.82) and aver-
age PA velocity (AUC 0.80) were the measurements
made from phase contrast sequence images with the
highest diagnostic accuracy for the detection of PH. PA
relative area change< 15% was sensitive (86%) and spe-
cific (70%) for the detection of the presence of PH. PA
retrograde flow greater than 0.3 L/min/m2 demonstrated
sensitivity (82%) and specificity (71%) for the detection
of pulmonary hypertension, more accurate than percent-
age retrograde flow with lower sensitivity (73%) and spe-
cificity (56%). PA area measured in systole (AUC 0.77)
was a weaker marker of PH than diastolic PA area (AUC
0.82). Table 5 presents sensitivity, specificity, positive
predictive value and negative predictive value and ROC
analysis for the MRI measurements. Table 5 presents the
CMR indices between subgroups of PH.
The bias between observers for CMR derived RV mass
was −2.1 g (standard deviation 10.8) with limits of agree-
ment −23.3 to 19.1 g. For VMI measurements the bias
between observers was 0.02 (standard deviation 0.1) with
limits of agreement of −0.21 to 0.24. See Figure 5.
The diagnostic accuracy of TRJV and echo derived
mPAP had good diagnostic accuracy for predicting the
presence of PH, AUC 0.86, and AUC 0.88 respectively,
Table 2 Demographics, RHC, Echocardiography and CMR
Data
No PH n=39 PH n=194
Demographics
Age (yrs) 61 ± 16 63 ± 15
Female (%) 56% 59%
WHO class I 3 (1.5%)
II 42 (21.6%)
III 127 (65.5%)
IV 22 (11.3%)
Invasive catheter measurements
mRAP (mmHg) 6 ± 3 11 ± 5†
mPAP (mmHg) 19 ± 3 45 ± 12†
PCWP (mmHg) 11 ± 5 12± 6
CO (L.min) 7.0 ± 1.8 5.1 ± 1.7†
CI (L.min.m-2) 3.7 ± 0.7 2.9 ± 0.9†
PVR (dyn.s.cm-5) 149± 167 587 ± 411†
Mixed VO2 (%) 73.5 ± 6.3 63.8 ± 9.2†
Echocardiography (n= 195)
TRJV (cm/s) 2.6 ± 0.6 3.9 ± 0.9†
Echo derived mPAP (mmHg) 25.4 ± 7.6 46.8 ± 16.6†
MR – RV morphology
RVEDVI (ml/m2) 77.7 ± 24.6 99.1 ± 39.0†
RV mass index (g/m2) 13.7 ± 6.92 37.6 ± 18.7†
VMI (ratio) 0.26 ± 0.11 0.70 ± 0.35†
Late gadolinium enhancement,
ratio and % (n = 159)
2/31 (6%) 108/128 (86%)
MR – RV function
RVEF (%) 39.7 ± 14.5 28.2 ± 14.5†
RVSVI (ml/m2) 31.4 ± 13.3 23.3 ± 13.2†
TAPSE (cm) 2.21 ± 0.66 1.55 ± 0.76†
f-TAAD (%) 24.6 ± 7.89 15.9 ± 7.49†
SFD (cm) 1.10 ± 0.45 0.64 ± 0.52†
f-SFD (%) 27.1 ± 11.5 14.4 ± 12.3†
RVRAC (%) 39.8 ± 10.5 26.2 ± 13.4†
sEI (ratio) 1.19 ± 0.19 1.57 ± 0.52†
dEI (ratio) 1.17 ± 0.12 1.28 ± 0.23
Phase contrast – Pulmonary artery (n = 106)
Average velocity (cm/s) 13.6 ± 6.7 7.6 ± 3.4†
Retrograde flow (L/min/m2) 0.2 ± 0.1 0.5 ± 0.3†
Retrograde flow (%) 9.3 ± 7.2 16.3 ± 9.2†
PA relative area change≥ 15% 17.8 ± 6.6 8.1 ± 6.5†
Systolic PA area (cm2) 7.8 ± 4.6 9.7 ± 2.8†
Diastolic PA area (cm2) 6.7 ± 4.7 8.9 ± 2.8†
Mean± SD values displayed, † tested value significantly different in the PH
patient group than in the ‘No PH’ group (p< 0.05).
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This study has demonstrated that VMI and sEI were the
CMR metrics with the strongest correlation with mPAP
and PVR in the largest population of patients with sus-
pected pulmonary hypertension studied to date undergo-
ing CMR as part of their routine diagnostic work-up.
VMI also demonstrated the highest diagnostic accuracy
for the diagnosis of PH of all measured MR indices. In
addition, late gadolinium enhancement at the inter-
ventricular hinge points was sensitive and specific for
the identification of PH and was present in 95% of
patients with IPAH and 97% of patients with CTPEH,
supporting a role for the routine measurement of these
MR metrics in patients undergoing diagnostic CMR
evaluation for suspected pulmonary hypertension.
CMR provides accurate and reproducible measure-
ments of RV morphology and function, including mass,
RVEDVI, RVEF, and RVSVI [25]. Currently manual RV
volume and mass measurements are preferred to semi-
automated methods with a manual technique showing
stronger inter-observer agreement [7]. This study sup-
ports previous work assessing RVEDVI,,RV mass index
and VMI which were all found to be elevated in PH
when compared to patients with ‘No PH’. RVEF and
RVSVI were significantly reduced compared to patients
with ‘No PH’ [26,27]. TRJV and estimated mPAP mea-
sured at echocardiography had a good correlation with
invasively measured mPAP and had high diagnostic ac-
curacy for the detection of PH confirming that both
echocardiography and CMR have diagnostic utility in
patients with suspected PH, However, echocardiography
and CMR may have limited value in an individual pa-
tient due for example to difficult acoustic windows or
claustrophobia, respectively.
In the work-up of patients with suspected PH CMR
may be particularly useful in patients in whom echocar-
diography is suboptimal, and this study identifies VMI
and late gadolinium enhancement as the metrics of
greatest diagnostic value. However, there is currently no
reliable fully automated method for calculating RV mass,
therefore RV muscle wall has to be manually segmented
on each SA image slice. This is a time consuming
process and is difficult to perform in patients with low
RV mass as the wall is thin and is difficult to accurately
measure, further work refining methods of determining
RV mass are required [8,9]. RV mass intuitively increases
over time due to elevated RV after load in patients with
PH. We postulate that RV hypertrophy is an adaption
mechanism of the RV in order to preserve function. The
temporal relationship between RV mass and pulmonary
artery pressure has not been fully described in the litera-
ture. The length of time an individual is exposed to high
pulmonary artery pressure and their response to this
increased after load will influence the degree of
Table 3 Subgroup analysis
Gp 1 IPAH
n=28
Gp 1 PAH-CTD
n=39
Gp 2 PH-LHD
n=21
Gp 3 RESP
n=29
Gp 4 CTEPH
n=59
Demographics and RHC
Age (yrs) 53 ± 17}, +, }, ƒ 67 ± 9# 74 ± 9# 67 ± 12# 64 ± 14#
mPAP (mmHg) 54 ± 13}, +, } 40 ± 13#, ƒ 35 ± 8#, ƒ 39 ± 8#, ƒ 49 ± 10}, +, }
PCWP (mmHg) 11 ± 3+ 11 ± 4+ 21 ± 4#, }, }, ƒ 12 ± 4+ 12 ± 5+
mRAP (mmHg) 11 ± 5 9 ± 5+ 14 ± 5}, } 9 ± 4+ 12 ± 6
CO (L.min) 4.6 ± 1.4+ 5.2 ± 1.6 6.2 ± 1.7#, ƒ 5.3 ± 1.3 4.8 ± 1.5+
CI (L.min.m-2) 2.5 ± 0.7}, + 3.1 ± 0.7#, ƒ 3.4 ± 0.8#, ƒ 3.0 ± 0.6 2.5 ± 0.7}, +
PVR (dyn.s.cm-5) 876± 439}, +, } 484 ± 337#, ƒ, + 183 ± 87}, #, ƒ, 428 ± 206#, ƒ 736 ± 373}, +, }
CMR
RVEDVI (ml/m2) 119 ± 47 82 ± 27+, ƒ 91 ± 38} 96 ± 33 108± 41}
VMI (ratio) 1.0 ± 0.4}, +, } 0.6 ± 0.4#, ƒ, + 0.3 ± 0.1#, ƒ, } 0.6 ± 0.2#, ƒ 0.8 ± 3.1}, +, }
RV mass index (g/m2) 50 ± 19}, +, } 27 ± 14#, ƒ 22 ± 11#, ƒ 32 ± 11#, ƒ 43 ± 16}, +, }
Late gadolinium enhancement
ratio and %
21/22 (95%)+ 20/28 (77%) 4/15 (27%)#, ƒ 19/20 (95%) 38/39 (97%)+
RVEF (%) 23 ± 15 32 ± 16 ƒ 32 ± 10 ƒ 24 ± 15 21 ± 12}, +
RVSVI (ml/m2) 26 ± 21 24 ± 14 29 ± 13 22 ± 13 21 ± 11
TAPSE (cm) 1.5 ± 0.5 1.6 ± 0.7 2.0 ± 0.6}, ƒ 1.4 ± 0.7+ 1.2 ± 0.5+
sEI (ratio) 2.2 ± 0.6}, +, }, ƒ 1.4 ± 0.4# 1.2 ± 0.2#, ƒ 1.3 ± 0.3#, ƒ 1.6 ± 0.5#,+, }
dEI (ratio) 1.5 ± 0.4}, +, }, ƒ 1.3 ± 0.2# 1.2 ± 0.2# 1.1 ± 0.1# 1.3 ± 0.3#
Average velocity (cm/s) 7.0 ± 3.0 10.0 ± 3.7 ƒ 9.1 ± 3.4 7.4 ± 3.4 5.9 ± 2.5}
Retrograde flow (L/min/m2) 0.5 ± 0.3 0.4 ± 0.3 0.5 ± 0.3 0.4 ± 0.2 0.5 ± 0.3
PA relative area change (%) 6 ± 5+ 9 ± 6 13 ± 10#, ƒ 8.2 ± 6.0 6.5 ± 4.0+
Systolic PA area (cm2) 9.4 ± 1.8 9.0 ± 2.1 9.0 ± 2.2 9.1 ± 1.9 9.9 ± 2.2
Diastolic PA area (cm2) 8.9 ± 1.8 8.1 ± 2.1 7.8 ± 2.0 8.2 ± 2.0 9.2 ± 2.0
Mean± standard deviation presented.
#: P< 0.05 in comparison to group 1, idiopathic pulmonary arterial hypertension (IPAH).
}: P< 0.05 in comparison to group 2, pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD).
+: P< 0.05 in comparison to group 3, pulmonary hypertension owing to left heart disease (PH-LHD).
}: P< 0.05 in comparison to group 4, pulmonary hypertension associated with lung disesae (PH-RESP).
ƒ: P< 0.05 in comparison to group 1, chronic thromboembolic pulmonary hypertension (CTEPH).
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RV mass and mPAP would be of particular value when
assessing RV responses to therapy.
Simple functional measurements such as left ventricular
eccentricity indices have the advantage over other moreFigure 3 Scatter plots showing the significant linear relationships of V
versus right heart catheter measured mPAP on the x-axis.labour intensive MR indices that they are easy and quick to
measure, and can be performed in routine clinical practice
whilst reviewing the SA images. Although these measure-
ments have been investigated with echocardiography, there
is little published evidence for their clinical utility usingMI and Echocardiography derived mPAP shown on the y-axis
Table 4 Correlations of CMR Parameters with mPAP and
PVR
mPAP
r value
p-value PVR
r value
p-value
Cardiac morphology
RVEDVI 0.39 <0.0001 0.42 <0.0001
RV mass index 0.74 <0.0001 0.65 <0.0001
VMI 0.78 <0.0001 0.74 <0.0001
Right heart functional indices
RVEF −0.43 <0.0001 −0.45 <0.0001
RVSVI −0.24 0.001 −0.21 0.003
TAPSE −0.40 <0.0001 −0.46 <0.0001
f-TAAD −0.53 <0.0001 −0.50 <0.0001
SFD −0.46 <0.0001 −0.40 <0.0001
f-SFD −0.55 <0.0001 −0.42 <0.0001
RVRAC −0.59 <0.0001 −0.56 <0.0001
sEI 0.71 <0.0001 0.66 <0.0001
dEI 0.45 <0.0001 0.43 <0.0001
Phase contrast CMR
Average velocity (cm/s) −0.55 <0.0001 −0.56 <0.0001
Retrograde flow (L/min/m2) −0.33 <0.0001 0.25 0.029
Percentage retrograde flow (%) −0.34 <0.0001 −0.31 0.001
PA relative area change (%) −0.54 <0.0001 −0.54 <0.0001
Systolic PA area (cm2) 0.28 0.001 0.17 0.054
Diastolic PA area (cm2) 0.35 <0.0001 0.26 0.003
Table 5 Sensitivity, Specificity, Positive and Negative
Predictive Values and area under the receiver operating
characteristic curve (AUC) of CMR Indices for the
Detection of PH
Sensitivity Specificity PPV NPV AUC
Cardiac morphology
RVEDV index≥ 75 ml/m2 67 50 89 20 0.72*
RV mass index≥ 20 g/m2 83 84 96 50 0.91*
VMI≥ 0.4 81 88 97 50 0.91*
Late gadolinium enhancement 83 94 98 58 0.89*
Right heart functional indices
RVEF≤ 35% 67 71 93 28 0.72*
RVSVI≤ 30 ml/m2 70 47 89 21 0.68*
TAPSE≤ 2 cm 76 64 92 32 0.75*
f-TAAD≤ 25% 88 56 92 44 0.78*
SFD≤ 1 cm 77 67 93 34 0.73*
f-SFD≤ 25% 79 64 92 35 0.78*
RVRAC≤ 30% 61 81 95 28 0.79*
sEI≥ 1.2 65 61 90 24 0.72*
dEI≥ 1.17 62 54 88 20 0.57
Phase contrast CMR
Average velocity≤ 10 (cm/s) 82 62 94 32 0.80*
Retrograde flow≥ 0.3 (L/min/m2) 83 71 95 38 0.84*
Retrograde flow (%) 73 56 87 34 0.75*
PA relative area change≥ 15% 86 70 94 48 0.87*
Systolic PA area≥ 8 cm2 74 67 92 32 0.77*
Diastolic PA area≥ 6 cm2 88 66 94 52 0.82*
AUC (area under the curve) *p< 0.05.
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measurements from echocardiography is accepted as chal-
lenging, validation of such measures with MRI is desirable.
sEI assesses the effect of the ventricular pressure differential
on the shape of the left ventricle, with values increasing as
the septum bows further to the left side deforming the LV
cavity and has been shown to correlate with pulmonaryFigure 4 ROC curves showing the diagnostic accuracy of VMI
and Echocardiography derived mPAP.arterial and RV pressure using echocardiography in patients
with PH [28]. Our MR derived sEI measurement correlated
strongly with mPAP and PVR as shown with echocardiog-
raphy [23,29,30]. We demonstrated similar results using
MRI to those found using echocardiography with a sEI
index >1.2 suggesting the presence of PH [23]. In patients
with mild elevations in mPAP, the ventricular pressure gra-
dient is not significant enough to cause paradoxical motion,
this in part explains the poor sensitivity of sEI to detect the
presence of PH and caution should be taken when inter-
preting sEI in patients with low mPAP.
Patients with PH have significantly more retrograde PA
flow and significantly reduced average PA velocity than
patients without PH. Retrograde PA flow >0.3 L/min/m2
and average velocity (10 cm/s) had reasonable diagnostic
accuracy for the detection of PH in this studyl. Sanz et al.
suggest that average velocity is the most robust phase con-
trast diagnostic measurement at the pulmonary artery [15],
with reduced average velocity and increased pulmonary ar-
tery area occurring simultaneously as a response to
increased pressure and resistance. However, retrograde flow
Figure 5 Bland Altman plots showing the agreement between two independent observers for ventricular mass index (VMI) and RV
mass index measurements.
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study, and our finding supports a recent study showing that
early retrograde flow is a characteristic feature in patients
with PH [31].
We have also summarised the differences in haemo-
dynamic and CMR parameters between the larger sub-
groups of patients in this study, Table 3. Patients with IPAH
and CTEPH had evidence of severe pulmonary hyperten-
sion at right heart catheter and 95% and 97% of patients
respectively had delayed myocardial enhancement demon-
strating that this metric is highly sensitive for the detection
of severe increases in RV after load seen IPAH and CTEPH.
Importantly qualitative assessment of late gadolinium en-
hancement can be performed rapidly. Patients with IPAH
and CTEPH had more severe disease at cardiac catheter
than patients with SSc-PAH and this is reflected in CMR
morphological findings with increased RV mass index and
increased VMI and more severe functional impairment
than in IPAH and CTEPH compared to PAH-CTD. There
is little published data of CMR RV findings in patients with
LV diastolic dysfunction. Importantly this study demon-
strates that VMI is low in these patients and they have
much better preserved cardiac function than patients with
pre-capillary disease such as IPAH and CTEPH where pul-
monary vascular resistance is significantly elevated. This is
likely to reflect the site of disease with patients with post-
capillary disease such as LHD only having minimally ele-
vated pulmonary vascular resistance despite high pressures.
The low prevalence of late gadolinium enhancement in
27% in patients with PH-LHD is consistent the primarily
post-capillary nature of pulmonary vascular disease in the
majority of these patients. Patents with PH-RESP had mod-
erate elevation of mPAP and PVR and elevated VMI and
impaired RV function consistent with a significant increase
in RV after load.
Limitations
The MRI measurements were acquired retrospectively.
Echocardiography was performed several weeks prior to
admission for RHC, this limits the direct comparison ofthe diagnostic accuracy of CMR versus echocardiog-
raphy for the detection of PH. Echocardiography is a
well-established screening tool in the evaluation of
patients with suspected PH, implementation of CMR as
a replacement for echocardiography would be associated
with several challenges, including cost, availability and
expertise. The control or “No PH” group includes
patients referred with suspected PH due to clinical
signs/symptoms or an abnormal echocardiogram sug-
gestive of PH, but were found to have a normal pulmon-
ary artery pressure at RHC. These patients frequently
had co-morbidities and cannot be considered to be
healthy controls. This importantly, however, represents
the target population that one would consider perform-
ing such diagnostic tests and prevents some of the errors
inherent in analysing data exclusively from particular
sub-groups. Several patients in the ‘No PH’ group, how-
ever, had right ventricular dysfunction on CINE cardiac
MRI scans in the absence of significant pulmonary vas-
cular disease which may have contributed to the reduced
accuracy of MR indices.
Conclusions
MRI is a robust alternative to echocardiography in the
evaluation of patients with suspected PH. VMI showed a
linear relationship with mPAP and had the highest ac-
curacy of all CMR measurements for the identification
of PH. Late gadolinium enhancement, PA relative area
change and retrograde flow are other useful markers that
should be evaluated in patients with suspected pulmon-
ary hypertension who undergo CMR.
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